Epiminder (ASX:EPI) said the first Diagnosing Epilepsy To Effect Change (DETECT) study was enrolled at the Perelman School of Medicine at the University of Pennsylvania, and the first patient in the US received an implant of the Minder system, an epilepsy diagnostic device using continuous electroencephalographic monitoring, according to a Monday Australian bourse filing.

The study will have a duration of six months, and 210 patients will receive the implant at up to 25 sites in the US. It will compare patients who are implanted with the system to standard-of-care monitoring to identify clinically actionable events in patients with drug-resistant epilepsy. Four other sites are recruiting for the study.

The firm's shares advanced 1% in recent trading on Monday.